keyword
MENU ▼
Read by QxMD icon Read
search

bortezomib neuropathy

keyword
https://www.readbyqxmd.com/read/28194052/once-weekly-1-6%C3%A2-mg-m-2-bortezomib-bcd-regimen-in-elderly-patients-with-newly-diagnosed-multiple-myeloma-who-are-unfit-for-standard-dose-chemotherapy
#1
Yong Tang, Ye-Hua Yu, Yi-Yun Yao, Li-Fang Zou, Hong-Ju Dou, Lei Wang, Qi Zhu
Bortezomib has shown anti-myeloma effects in combination with alkylating agents, but clinical benefits can be limited by neurotoxicity. There is less information on the efficacy and tolerability of once-weekly 1.6 mg/m(2) bortezomib combined with cyclophosphamide and dexamethasone (BCD) regimen in elderly patients with newly diagnosed multiple myeloma who are unfit for standard dose chemotherapy. Here, we report our experience of weekly 1.6 mg/m(2) intravenous bortezomib in this group of patients. Between March 2010 and February 2015, we treated 34 newly diagnosed elderly patients with the combination of bortezomib 1...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28169430/phase-ii-study-of-bendamustine-bortezomib-and-dexamethasone-bbd-in-the-first-line-treatment-of-patients-with-multiple-myeloma-who-are-not-candidates-for-high-dose-chemotherapy
#2
Jesus G Berdeja, Todd Bauer, Edward Arrowsmith, James Essell, Patrick Murphy, James A Reeves, Ralph V Boccia, William Donnellan, Ian Flinn
The combination of bendamustine, bortezomib and dexamethasone (BBD) was evaluated as a first-line therapy for multiple myeloma. The original treatment regimen of bendamustine 80 mg/m(2) , days 1, 4; bortezomib 1·3 mg/m(2) , days 1, 4, 8, 11; dexamethasone 40 mg, days 1, 2, 3, 4 on a 28-day cycle (up to 8 cycles) was efficacious but determined relatively toxic in an interim analysis. The regimen was amended to bendamustine 80 mg/m(2) , days 1, 2; bortezomib 1·3 mg/m(2) , days 1, 8, 15; dexamethasone 20 mg, days 1, 2, 8, 9, 15, 16 every 28 days (up to 8 cycles), then maintenance 1·3 mg/m(2) IV bortezomib every 2 weeks...
February 7, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28152765/evaluation-of-relative-thrombocytopenia-identification-of-neuropathy-and-bleeding-risk-secondary-to-utilization-of-neuromodulating-agents-in-multiple-myeloma-patients-receiving-autologous-stem-cell-transplant-treated-with-melphalan-bortezomib-and-lenalidomide
#3
Joel Marcus, Robyn Jackson, Marco A Ruiz, Ryan Patrick Griffin, Rubina Hafeez Khan
: 212 Background: Chemotherapy-induced polyneuropathy (CIPN) is a crippling manifestation in multiple myeloma (MM) patients that requires attentiveness to safety and quality of life.(2) Bortezomib, lenalidomide, and melphalan are commonly utilized chemotherapy agents that can cause both CIPN(3,4) and significant myelosuppression. Within this subset of patients we wish to insure efficacy and minimization of neuropathic pain while being mindful of bleeding risks. METHODS: IRB approval was obtained for a retrospective study of patients with MM who received a bone marrow transplant (BMT)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28127506/chemotherapy-induced-neuropathies-a-growing-problem-for-patients-and-health-care-providers
#4
Marta Banach, Judyta K Juranek, Aneta L Zygulska
INTRODUCTION: Chemotherapy-induced neuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. Chemotherapy effects on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. The three most neurotoxic classes of anti-cancer drugs are: platinum-based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids...
January 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28115644/multiparametric-image-analysis-of-rat-dorsal-root-ganglion-cultures-to-evaluate-peripheral-neuropathy-inducing-chemotherapeutics
#5
Liang Guo, John Hamre, Sandy Eldridge, Holger P Behrsing, Facundo M Cutuli, Jodie Mussio, Myrtle Davis
Chemotherapy-induced peripheral neuropathy (CIPN) is a major, dose-limiting adverse effect experienced by cancer patients. Advancements in mechanism-based risk mitigation and effective treatments for CIPN can be aided by suitable in vitro assays. To this end, we developed a multiparametric morphology-centered rat dorsal root ganglion (DRG) assay. Morphologic alterations in subcellular structures of neurons and non-neurons were analyzed with an automated microscopy system. Stains for NeuN (a neuron-specific nuclear protein) and Tuj-1 (β-III tubulin) were used to identify neuronal cell nuclei and neuronal cell bodies/neurites, respectively...
January 22, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/28111466/bortezomib-and-thalidomide-maintenance-after-stem-cell-transplantation-for-multiple-myeloma-a-pethema-gem-trial
#6
L Rosiñol, A Oriol, A I Teruel, A L de la Guía, MaJ Blanchard, J de la Rubia, M Granell, MaA Sampol, L Palomera, Y González, MaA Etxebeste, R Martínez-Martínez, M T Hernández, F de Arriba, A Alegre, MaT Cibeira, MaV Mateos, J Martínez-López, J J Lahuerta, J San Miguel, J Bladé
The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide/dexamethasone, bortezomib/thalidomide/dexamethasone and Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone bortezomib (VBMCP/VBAD/B) followed by autologous stem cell transplantation (ASCT) with MEL-200. After ASCT, a second randomization was performed to compare thalidomide/bortezomib (TV), thalidomide (T) and alfa-2b interferon (alfa2-IFN)...
February 14, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28079515/efficacy-and-safety-of-subcutaneous-versus-intravenous-bortezomib-in-multiple-myeloma-a%C3%A2-meta-analysis%C3%A2
#7
Bin Hu, Quan Zhou, Tao Wu, Lan Zhuang, Liping Yi, Jinxia Cao, Xin Yang, Jun Wang
PURPOSE: We performed this meta-analysis to compare the efficacy and safety between two different administration routes of bortezomib, subcutaneous and intravenous. METHODS: Six retrospective studies and three randomized controlled trials (RCTs) were included in our study. Data from retrospective studies or RCTs were pooled and displayed in their corresponding subgroup, retrospective studies subgroup or RCTs subgroup. We comprehensively compared the overall response rate (ORR) and the incidence of adverse events between subcutaneous and intravenous bortezomib...
January 12, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28076695/deacetylase-inhibitors-an-advance-in-myeloma-therapy
#8
Jacob P Laubach, Jesus F San-Miguel, Vania Hungria, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Melissa Alsina, Paul G Richardson
A significant unmet need exists in patients with relapsed or refractory multiple myeloma (MM), which remains an incurable disease despite recent advances in the field. One such development was the use of deacetylase inhibitors (DACi), which exert unique antimyeloma effects through targeting of epigenetic and protein metabolism pathways. The pan-DACi panobinostat was recently approved in combination with bortezomib and dexamethasone for use in patients with relapsed or relapsed and refractory MM. Results of a phase 3 trial showed that the panobinostat-containing regimen improved the overall response rate and progression-free survival...
February 1, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28056114/diagnosis-and-management-of-waldenstr%C3%A3-m-macroglobulinemia-mayo-stratification-of-macroglobulinemia-and-risk-adapted-therapy-msmart-guidelines-2016
#9
Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A Kyle, Shaji K Kumar, Joseph R Mikhael, Thomas E Witzig, Michelle Mauermann, Angela Dispenzieri, Sikander Ailawadhi, A Keith Stewart, Martha Q Lacy, Carrie A Thompson, Francis K Buadi, David Dingli, William G Morice, Ronald S Go, Dragan Jevremovic, Taimur Sher, Rebecca L King, Esteban Braggio, Ann Novak, Vivek Roy, Rhett P Ketterling, Patricia T Greipp, Martha Grogan, Ivana N Micallef, P Leif Bergsagel, Joseph P Colgan, Nelson Leung, Wilson I Gonsalves, Yi Lin, David J Inwards, Suzanne R Hayman, Grzegorz S Nowakowski, Patrick B Johnston, Steven J Russell, Svetomir N Markovic, Steven R Zeldenrust, Yi L Hwa, John A Lust, Luis F Porrata, Thomas M Habermann, S Vincent Rajkumar, Morie A Gertz, Craig B Reeder
Importance: Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system. Observations: Waldenström macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course...
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/27882113/peripheral-neuropathy-outcomes-and-efficacy-of-subcutaneous-bortezomib-when-combined-with-thalidomide-and-dexamethasone-in-the-treatment-of-multiple-myeloma
#10
Hong Liu, Ruirong Xu, Hongming Huang
Due to the safety, convenience and efficacy of subcutaneous administration of bortezomib (scBor), it is becoming increasingly common to treat multiple myeloma (MM) using this treatment method. The current retrospective study suggested a lower incidence of peripheral neuropathy (PN) outcomes and superior efficacy following treatment with scBor combined with thalidomide and dexamethasone (VTD) in MM when compared with intravenous Bor (ivBor) treatment. The data of 81 patients from the Affiliated Hospital of Nantong University between September 2011 and February 2014 were analyzed, including 37 scBor and 44 ivBor patients administered a median (range) of 5...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27856369/outcomes-of-maintenance-therapy-with-bortezomib-after-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma
#11
Dharshan Sivaraj, Michael M Green, Zhiguo Li, Anthony D Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn D Long, Mitchell E Horwitz, Richard D Lopez, Keith M Sullivan, David A Rizzieri, Nelson J Chao, Cristina Gasparetto
Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to the safety and efficacy of this agent compared with lenalidomide in the post-ASCT setting are limited. Therefore, we retrospectively analyzed the outcomes of 102 patients with MM who received maintenance therapy with bortezomib after ASCT at Duke University's adult bone marrow transplant clinic between 2005 and 2015...
February 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27820922/a-multicenter-phase-ii-study-of-twice-weekly-bortezomib-plus-rituximab-in-patients-with-relapsed-follicular-lymphoma-long-term-follow-up
#12
MULTICENTER STUDY
Alessia Bari, Raffaella Marcheselli, Luigi Marcheselli, Isabel Alvarez, Samantha Pozzi, Paola Ferri, Antonio Lazzaro, Alberto Fragasso, Santo Neri, Luca Baldini, Angelo Michele Carella, Francesco Angrilli, Roberto Guariglia, Gabriele Buda, Caterina Stelitano, Stefano Sacchi
Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed/refractory indolent lymphoma. On the basis of these findings, we performed a phase II study of B combined with rituximab (R) in patients with relapsed follicular lymphoma (FL). Forty-five patients with fairly good prognostic profiles were enrolled from 2007 to 2011 and received a total of 6 cycles of the B+R combination. The endpoints were the overall response rate (ORR), progression-free survival (PFS), duration of remission (DoR), overall survival (OS), and toxicity evaluation...
2017: Acta Haematologica
https://www.readbyqxmd.com/read/27746443/the-addition-of-low-dose-thalidomide-to-bortezomib-and-dexamethasone-for-refractory-multiple-myeloma
#13
Shigeo Hashimoto, Takashi Kuroha, Toshio Yano, Naoko Sato, Tatsuo Furukawa
Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27659525/a-dose-increased-once-weekly-bortezomib-based-combination-therapy-for-multiple-myeloma
#14
Daolin Wei, Yin Tong, Haitao Bai, Qi Cai, Yanrong Gao, Chun Wang
BACKGROUND: The purpose of the current study was to evaluate the efficacy and safety of a dose increased weekly Bortezomib (Bor) based combination therapy in multiple myeloma (MM) patients. RESULTS: The overall response rate (ORR) in the modified Bor group was 76.6%, composed of 40% complete response (CR), 3.3% very good partial response (VGPR) and 33.3% partial response (PR). The ORR was 82.3%, with 26.5% CR, 5.9% VGPR and 50% PR in control. A subgroup analysis showed both groups had equal efficacy in newly diagnosed MM patients ( P = 1...
September 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/27605156/prediction-of-peripheral-neuropathy-in-multiple-myeloma-patients-receiving-bortezomib-and-thalidomide-a-genetic-study-based-on-a-single-nucleotide-polymorphism-array
#15
Ramón García-Sanz, Luis Antonio Corchete, Miguel Alcoceba, María Carmen Chillon, Cristina Jiménez, Isabel Prieto, María García-Álvarez, Noemi Puig, Immaculada Rapado, Santiago Barrio, Albert Oriol, María Jesús Blanchard, Javier de la Rubia, Rafael Martínez, Juan José Lahuerta, Marcos González Díaz, María Victoria Mateos, Jesús Fernando San Miguel, Joaquín Martínez-López, María Eugenia Sarasquete
Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors for TiPN in MM patients include advanced age, prior neuropathy, and other drugs, but there are conflicting results about the role of genetics in predicting the risk of TiPN. Thus, we carried out a genome-wide association study based on more than 300 000 exome single nucleotide polymorphisms in 172 MM patients receiving therapy involving bortezomib and thalidomide...
September 8, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27590107/a-phase-i-ii-study-of-escalating-doses-of-bortezomib-in-conjunction-with-high-dose-melphalan-as-a-conditioning-regimen-for-salvage-autologous-peripheral-blood-stem-cell-transplantation-in-patients-with-multiple-myeloma
#16
Noa Biran, Scott D Rowley, David H Vesole, Shijia Zhang, Michele L Donato, Joshua Richter, Alan P Skarbnik, Andrew Pecora, David S Siegel
Escalating doses of bortezomib with high-dose melphalan was evaluated as as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with relapsed or refractory multiple myeloma (MM). MM patients with less than a partial remission (PR) (or 50% reduction) compared to their pretransplantation paraprotein parameters after a prior ASCT with melphalan conditioning, or who were in relapse after a prior autologous transplantation, were eligible for study. Bortezomib was dose escalated in steps of 1, 1...
August 31, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27540135/peripheral-neuropathy-associated-with-subcutaneous-or-intravenous-bortezomib-in-patients-with-newly-diagnosed-myeloma-treated-within-the-gmmg-mm5-phase-iii-trial
#17
LETTER
Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt
No abstract text is available yet for this article.
December 2016: Haematologica
https://www.readbyqxmd.com/read/27527836/immunoglobulin-light-chain-amyloidosis-2016-update-on-diagnosis-prognosis-and-treatment
#18
Morie A Gertz
DISEASE OVERVIEW: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma. DIAGNOSIS: Tissue biopsy stained with Congo red demonstrating amyloid deposits with applegreen birefringence is required for diagnosis...
September 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27475880/neuropathic-pain-in-cancer-patients-treated-with-bortezomib
#19
S Expósito Vizcaíno, J Casanova-Mollà, L Escoda, S Galán, J Miró
INTRODUCTION: The neuropathic pain is the most habitual problem in the neuropathy induced by chemotherapy (NIQ) and the one that more interferes in the quality of life of the patients. His precocious detection turns out to be fundamental to reduce or to eliminate the problems that from this one stem. The aims of this study were: 1) determine the incident and NIQ's characteristics and neuropathic pain in patients with mieloma multiple (MM) treated with bortezomib, and 2) to evaluate the impact of the neuropathic pain in the activities of the daily life (AVD)...
July 27, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/27473042/evolution-of-management-and-outcomes-in-waldenstr%C3%A3-m-macroglobulinemia-a-population-based-analysis
#20
Adam J Olszewski, Steven P Treon, Jorge J Castillo
INTRODUCTION: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM) is a rare lymphoma affecting older patients. Its management largely relies on small phase II trials and it is unclear how their results translate into clinical practice in the community. METHOD: We evaluated changes in the presentation, management, and survival among 2,666 Medicare beneficiaries diagnosed with WM between 1994 and 2011, using Medicare claims linked to Surveillance, Epidemiology and End Results data...
July 29, 2016: Oncologist
keyword
keyword
43865
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"